In a report released yesterday, Geoff Meacham from Barclays maintained a Sell rating on United Therapeutics (NASDAQ: UTHR), with a price target of $95. The company’s shares opened today at $102.97, close to its 52-week low of $101.99.
According to TipRanks.com, Meacham is a 3-star analyst with an average return of 3.5% and a 51.1% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Johnson & Johnson, and Seattle Genetics.
United Therapeutics has an analyst consensus of Hold, with a price target consensus of $135.83.
See today’s analyst top recommended stocks >>
Based on United Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $389 million and quarterly net profit of $245 million. In comparison, last year the company earned revenue of $371 million and had a net profit of $179 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. engages in the development and commercialization of innovative products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension, high-risk neuroblastoma.
